<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439982</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00060782</org_study_id>
    <nct_id>NCT03439982</nct_id>
  </id_info>
  <brief_title>Fecal Transplant for Hepatic Encephalopathy</brief_title>
  <official_title>A Prospective Single Center Open Label Trial of RBX2660 (Microbiota Suspension) in the Management of Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rebiotix Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if fecal microbiota transplant (FMT) can reverse
      hepatic encephalopathy (HE) in cirrhotic patients who continue to have breakthrough episodes
      of HE despite maintenance therapy with lactulose and/or rifaximin or metronidazole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects receive FMT from a single donor by colonoscopy at week 0 and by enema at weeks 1-4.
      HE is measured by Inhibitory Control Test (ICT) and Stroop test as well as fasting serum
      ammonia levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2016</start_date>
  <completion_date type="Anticipated">April 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 12, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to HE breakthrough</measure>
    <time_frame>9 weeks</time_frame>
    <description>Duration from FMT to overt HE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICT</measure>
    <time_frame>9 weeks</time_frame>
    <description>Changes in ICT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop</measure>
    <time_frame>9 weeks</time_frame>
    <description>Changes in Stroop test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ammonia</measure>
    <time_frame>9 weeks</time_frame>
    <description>Changes in serum ammonia level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>9 weeks</time_frame>
    <description>Changes in Chronic Liver Disease Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>FMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label FMT administered at week 0 by colonoscopy and weeks 1-4 by enema</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FMT</intervention_name>
    <description>FMT processed from routinely screened donors</description>
    <arm_group_label>FMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult cirrhotic patients of various etiology on lactulose and/pr rifaximin or
             metronidazole for minimum 4 weeks as secondary prophylaxis

          -  Abnormal ICT (&gt;5 lures) or abnormal Stroop test (&gt;200 seconds)

          -  Baseline Conn score 0 or 1

          -  Infectious etiology of HE has been ruled out

        Exclusion Criteria:

          -  those with tense ascites

          -  those who do not provide assent

          -  life expectancy &lt;3 months

          -  TIPS within the past 3 months

          -  neurologic disease such as dementia, Parkinson's, structural brain lesions

          -  pregnancy

          -  intestinal obstruction

          -  alcoholic hepatitis

          -  active alcohol or substance abuse

          -  those without stable social support

          -  concurrent infection such as spontaneous bacterial peritonitis, pneumonia or urinary
             tract infection

          -  creatinine clearance less that 50% compared to baseline

          -  hospital admission for HE within one month of enrollment

          -  active hepatocellular carcinoma

          -  active GI bleed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina Kao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dina Kao, MD</last_name>
    <phone>780 492 8307</phone>
    <email>dkao@ualberta.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Kao, MD</last_name>
      <phone>780 492 8307</phone>
      <email>dkao@ualberta.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2018</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic encephalopathy, fecal microbiota transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

